Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects

European Journal of Clinical Pharmacology

Volumn 59, Issue 1, 2003, Pages 35-43

  Eriksson, Ulf G ^a   Bredberg, Ulf ^a   Gislén, Kristina ^a   Johansson, Linda C ^a   Frison, Lars ^a   Ahnoff, Martin ^a   Gustafsson, David ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

Melagatran; Oral direct thrombin inhibitor; Ximelagatran

Indexed keywords

COUMARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; MELAGATRAN; THROMBIN INHIBITOR; XIMELAGATRAN;

ADULT; ANTICOAGULATION; AREA UNDER THE CURVE; ARTICLE; BLEEDING; BLEEDING TIME; CAPILLARY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG TOLERABILITY; FOOD DRUG INTERACTION; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PARTIAL THROMBOPLASTIN TIME; PHARMACODYNAMICS; PRIORITY JOURNAL; REPRODUCIBILITY; SIDE EFFECT; THROMBOEMBOLISM; TIME;

EID: 0013432360     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-003-0565-7     Document Type: Article

References (21)

1. Williams GR, Jiang JG, Matchar DB, Samsa GP (1999) Incidence and occurrence of total (first-ever and recurrent) stroke. Stroke 30:2523-2528
2. Tarazzi L (1999) Clinical epidemiology of acute myocardial infarction. Am Heart J 138:S48-S54
3. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ (1998) Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 158:585-593
4. Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B, Forcier A, Dalen JE (1991) A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 151:933-938
5. Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, Granger C, Ohman EM, Dalen JE (2001) Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 119:S64-S94
6. Hirsh J, Dalen J, Anderson DR, Poller L, Bussey H, Ansell J, Deykin D (2001) Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 119:S8-S21
7. Agnelli G, Mancini GB, Biagini D (2000) The rationale for long-term prophylaxis of venous thromboembolism. Orthopedics 23:S643-S646
8. Weitz JI, Hirsh J (2001) New anticoagulant drugs. Chest 119:S95-S107
9. Elg M, Gustafsson D, Deinum J (1997) The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis. Thromb Haemost 78:1286-1292
10. Elg M, Gustafsson D, Carlsson S (1999) Antithrombotic effects and bleeding time of thrombin inhibitors and warfarin in the rat. Thromb Res 94:187-197
11. Gustafsson D, Antonsson T, Bylund R, Eriksson U, Gyzander E, Nilsson I, Elg M, Mattsson C, Deinum J, Pehrsson S, Karlsson O, Nilsson A, Sorensen H (1998) Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes. Thromb Haemost 79:110-118
12. Metha JL, Chen L, Nichols WW, Mattsson C, Gustafsson D, Saldeen TG (1998) Melagatran, an oral active-site inhibitor of thrombin, prevents or delays formation of electrically induced occlusive thrombus in the canine coronary artery. J Cardiovasc Pharmacol 31:345-351
13. Eriksson BI, Carlsson S, Halvarsson M, Risberg B, Mattsson C (1997) Antithrombotic effect of two low-molecular-weight thrombin inhibitors and a low-molecular-weight heparin in a caval vein thrombosis model in the rat. Thromb Haemost 78:1404-1407
14. Mattsson C, Björkman JA, Ulvinge JC (1997) Melagatran, hirudin and heparin as adjuncts to tissue-type plasminogen activator in the canine model of coronary artery thrombolysis. Fibrinol Proteolys 11:121-1218
15. Eriksson H, Eriksson UG, Frison L, Hansson PO, Held P, Holmström M, Hagg A, Jonsson T, Lapidus L, Leijd B, Stockelberg D, Safwenberg U, Taghavi A, Thorsen M (1999) Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT. Thromb Haemost 81:358-363
16. Eriksson BI, Ögren M, Eriksson UG, Kälebo P, Ahnfelt L, Björkström S, Sjöstedt Å, Folestad A, Arfwidsson A-C, Elvander CS, Frison L (2002). Prophylaxis of venous thromboembolism with subcutaneous melagatran in total hip or total knee replacement: results from Phase II studies. Thromb Res 105:371-378
17. Eriksson BI, Arfwidsson A-C, Frison L, Eriksson UG, Bylock A, Kälebo P, Fager G, Gustafsson D (2002) A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery. Thromb Haemost 87:231-237
18. Eriksson BI, Bergqvist D, Kälebo P, Dahl OE, Lindbratt S, Bylock A, Frison L, Eriksson UG, Welin L, Gustafsson D (2002) Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet 360:1441-1447
19. Bredberg U, Eriksson U, Taure K, Frison L, Gustafsson D (1999) Effects of melagatran, a novel direct thrombin inhibitor, in healthy volunteers following intravenous, subcutaneous and oral administration. Blood 94:28a
20. Gustafsson D, Nyström J-E, Carlsson S, Bredberg U, Eriksson U, Gyzander E, Elg M, Antonsson T, Hoffmann K, Ungell A, Sorensen H, Nagard S, Abrahamsson A, Bylund R (2001) The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb Res 101:171-181
21. Larsson M, Logren U, Ahnoff M, Lindmark B, Abrahamsson P, Svennberg H, Persson B-A (2002) Determination of melagatran, a novel, direct thrombin inhibitor, in human plasma and urine by liquid chromatography-mass spectrometry. J. Chromatogr B 766:47-55